目的探讨胆管型细胞角蛋白7（CK7）在原发性肝癌中的表达状况和意义。
Objective To identify the expression of bile duct-type cytokeratin 7 (CK7) and explore its implications in primary hepatic carcinoma.
目的：探讨胆管细胞型肝癌的CT表现。
Purpose: To evaluate the CT imaging findings of intrahepatic cholangiocarcinoma.
目的探讨伴胆管癌栓的原发性肝癌（HCC）外科治疗方式的选择及对预后的影响。
Objectives To summarize the experience of surgical intervention for hepatocellular carcinoma(HCC) with bile duct thrombi(BDT), and to evaluate the influence on prognosis.
目的建立SD大鼠肝癌侵袭胆管所致恶性梗阻性黄疸模型，初步评价其临床应用价值。
Objective to establish malignant biliary obstruction model on the SD rats and to discuss its value and effect in the clinical application.
肝癌可具有肝细胞分化和胆管分化。
A liver cancer may have both hepatocellular as well as cholangiolar differentiation.
结果本组引起梗阻性黄疸性的疾病，分别为胆管结石、胆管癌、胰头癌、胆囊癌及肝癌。
Results the causes of obstructive jaundice in this study included cholelithes, cholangiocarcinoma, carcinoma of head of pancreas, carcinoma of gallbladder and hepatoma.
目的：观察胆管癌栓清除术或加肝癌切除术治疗原发性肝癌伴胆管癌栓的疗效。
Objective to summarize the methods of diagnosis and treatment for primary hepatocellular carcinoma (PHC) with tumor thrombus in the bile duct (TTBD).
胆管细胞性肝癌中10 0 % （3 /3 ）在连续成像上呈现造影增强，显示的肿瘤血管较粗大；间歇成像则显示66.7% （2 /3 ）造影增强。
In similar, 100% (3/3) cholangiocarcinomas were enhanced on continuous imaging of CHA and 66.7 % (2/3) on interval imaging, and their tumor vessels were relatively large.
结论对肝癌侵犯胆管形成癌栓者及时诊断，尽早切除肿瘤、清除癌栓是一种积极有效的治疗方法。
Conclusion Accurate diagnosis and radical hepatectomy with complete BDT clearance are effective treatment for HCC with BDT.
结论：原发性肝癌合并胆管癌栓的患者明确诊断后行积极的外科治疗，可获得较好的治疗效果。
Conclusions: Patients with hepatocellular carcinoma and tumor thrombus of bile duct can obtain a good outcome after definitive diagnosis and aggressive surgical treatment.
目的：观察胆管癌栓清除术或加肝癌切除术治疗原发性肝癌伴胆管癌栓的疗效。
Objective To evaluate the effect of surgical treatment for primary hepatocellular carcinoma(HCC) with bile duct thrombi(BDT).
其中肝细胞性肝癌77例(84.6%)，胆管癌9例(9.9%)，混合细胞性肝癌2例(2.2%)和肝母细胞瘤3例(3.3%)。
Among all the cases studies, 77 (84.6%) were of hepatocellular carcinoma, 9 (9.9%) of cholangiocarcinoma, 2 (2.2%) of mixed cell carcinoma, and 3 (3.3%;) of hepatoblastoma.
其中肝细胞性肝癌77例(84.6%)，胆管癌9例(9.9%)，混合细胞性肝癌2例(2.2%)和肝母细胞瘤3例(3.3%)。
Among all the cases studies, 77 (84.6%) were of hepatocellular carcinoma, 9 (9.9%) of cholangiocarcinoma, 2 (2.2%) of mixed cell carcinoma, and 3 (3.3%;) of hepatoblastoma.
应用推荐